

- parison with computed tomography and gallium-67 single photon emission computed tomography. *Clin Lymphoma*. 2000;1:67–74.
14. Spaepen K, Stroobants S, Verhoef G, Mortelmans L. Positron emission tomography with [¹⁸F]FDG for therapy response monitoring in lymphoma patients. *Eur J Nucl Med Mol Imaging*. 2003;30(suppl 1):S97–S105.
 15. Ullerich H, Franzius CH, Domagk D, et al. ¹⁸F-Fluorodeoxyglucose PET in a patient with primary small bowel lymphoma: the only sensitive method of imaging. *Am J Gastroenterol*. 2001;96:2497–2499.
 16. Hoffmann M, Vogelsang H, Kletter K, Zettinig G, Chott A, Raderer M. ¹⁸F-fluoro-deoxy-glucose positron emission tomography (¹⁸F-FDG-PET) for assessment of enteropathy-type T cell lymphoma. *Gut*. 2003;52:347–351.
 17. Levine MS, Rubesin SE, Pantongrag-Brown L, Buck JL, Herlinger H. Non-Hodgkin's lymphoma of the gastrointestinal tract: radiographic findings. *AJR*. 1997;168:165–172.
 18. Becherer A, Jaeger U, Szabo M, Kletter K. Prognostic value of FDG-PET in malignant lymphoma. *Q J Nucl Med*. 2003;47:14–21.
 19. Van Den Bossche B, Lambert B, De Winter F, et al. ¹⁸FDG PET versus high-dose ⁶⁷Ga scintigraphy for restaging and treatment follow-up of lymphoma patients. *Nucl Med Commun*. 2002;23:1079–1083.
 20. Friedberg JW, Chengazi V. PET scans in the staging of lymphoma: current status. *Oncologist*. 2003;8:438–447.
 21. Romer W, Schwaiger M. Positron emission tomography in diagnosis and therapy monitoring of patients with lymphoma. *Clin Positron Imaging*. 1998;1:101–110.
 22. Reske SN. PET and restaging of malignant lymphoma including residual masses and relapse. *Eur J Nucl Med Mol Imaging*. 2003;30(suppl 1):S89–S96.
 23. Guay C, Lepine M, Verreault J, Benard F. Prognostic value of PET using ¹⁸F-FDG in Hodgkin's disease for posttreatment evaluation. *J Nucl Med*. 2003;44:1225–1231.
 24. Cremerius U, Fabry U, Kroll U, et al. Clinical value of FDG PET for therapy monitoring of malignant lymphoma: results of a retrospective study in 72 patients. *Nuklearmedizin*. 1999;38:24–30.
 25. Moog F, Bangerter M, Diederichs CG, et al. Extranodal malignant lymphoma: detection with FDG PET versus CT. *Radiology*. 1998;206:475–481.
 26. Golder W. Positron emission tomography and lymphoma therapy. *Onkologie*. 2001;24:496–498.
 27. O'Doherty MJ, Macdonald EA, Barrington SF, Mikhaeel NG, Schey S. Positron emission tomography in the management of lymphomas. *Clin Oncol (R Coll Radiol)*. 2002;14:415–426.
 28. Sam JW, Levine MS, Farner MC, Schuster SJ, Alavi A. Detection of small bowel involvement by mantle cell lymphoma on F-18 FDG positron emission tomography. *Clin Nucl Med*. 2002;27:330–333.
 29. Hoffmann M, Chott A, Puspok A, Jager U, Kletter K, Raderer M. ¹⁸F-fluorodeoxyglucose positron emission tomography (¹⁸F-FDG-PET) does not visualize follicular lymphoma of the duodenum. *Ann Hematol*. 2003;83:276–278.
 30. Hoffmann M, Kletter K, Diemling M, et al. Positron emission tomography with fluorine-18–2-fluoro-2-deoxy-D-glucose (F18-FDG) does not visualize extranodal B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT)-type. *Ann Oncol*. 1999;10:1185–1189.
 31. Rodriguez M, Ahlstrom H, Sundin A, et al. [¹⁸F]FDG PET in gastric non-Hodgkin's lymphoma. *Acta Oncol*. 1997;36:577–584.



Errata

In the article “The Role of ¹⁸F-FDG PET in Staging and Early Prediction of Response to Therapy of Recurrent Gastrointestinal Stromal Tumors,” by Gayed et al. (*J Nucl Med*. 2004;45:17–21), Tables 1 and 2 contain errors. In Table 1, the column headers “CT” and “FDG PET” should have been transposed, and in Table 2, the number of false-negative FDG PET findings should have been reported as 24, not 25. The authors regret the errors.

Because of a proofreading oversight, the book review “IAEA Quality Control Atlas for Scintillation Camera Systems,” by William D. Erwin (*J Nucl Med*. 2004;45:1792) failed to name the author of the book, Ellinor Busemann Sokole, PhD, of Academic Medical Center, Amsterdam, The Netherlands. We regret the error.